GSK studying if best-selling shingles vaccine lowers dementia risk

General view outside GlaxoSmithKline headquarters in Brentford, London, Britain, May 4, 2020. — Reuters

LONDON: GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its best-selling shingles vaccine lowers the risk of…


Source link